Exchange: NASDAQ·Updated 10:08 AM EDT

IONS News

News
all
press releases
Ionis Drug Wins FDA Approval as First Alexander Disease Treatment
FDA approves Zanvastro from Ionis Pharmaceuticals as the first disease-modifying treatment for rare Alexander disease.read more...
Benzinga
More News
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout
Wall Street removed the Angelman program from valuation models, slashing price targets by as much as 76% and issuing multiple downgrades.
Stocktwits
ZANVASTRO (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved ZANVASTRO (zilganersen) for the treatment of Alexander disease (AxD) in pediatric and adult patients. ZANVASTRO is the first and only disease modifying treatment for AxD, an...
Business Wire
IONS Edges Up After-Hours On FDA’s Green Light For Neurology Drug After Being Dragged Down By Ultragenyx’s Failed Trial
Zanvastro is now approved for children and adults with Alexander disease, a rare and often fatal brain condition that affects fewer than one in a million people.
Stocktwits
Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 21st Annual Wells Fargo Healthcare Conference on Thursday, September 10, 2026 Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday...
Business Wire
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone
Key PointsIonis experienced a double-whammy in July with two clinical setbacks...
Nasdaq News: Markets
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
Indivior Pharmaceuticals Inc. (INDV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Friday.
Stocktwits
Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC)Congress 2026, taking place August 28 31 in Munich. Presentations include one-year data from the open-label...
Business Wire

Advertisement|Remove ads.